Pharmaceutical Companies

Republicans should unify behind one approach with the potential to be decisive for anyone who isn't a hard partisan. That approach is to promote the right to know health care prices up front—health care price transparency.

"The vast costs associated with health care represent one of the most important and contentious issues facing Americans today," said researcher Joseph Dieleman.

For starters, taking the company private could take more than $55 billion in debt, a tough move to finance amid slumping stocks.

One key factor is that people only take antibiotics for a short period of time, just until an infection clears.

What will it take for pharmaceutical companies to create a viable strep vaccine?

Azar will be replacing Tom Price, the former HHS secretary who resigned amid a private plane scandal in September.

Democracy Forward is suing for details about a former pharmaceutical lobbyist's role in drug regulation.

The maker of Botox has been accused of unethical practices—but those accusations are also raising suspicions.

The former supervisor of now-defunct New England Compounding Center could receive a life sentence for second-degree murder in case linked to the deaths of more than 70 people.

Pharmacy benefit managers arose to fulfill a need created by the Medicare Modernization Act. But now these companies are contributing to escalating drug prices, the very opposite of their original purpose.

Without laws to enforce them, the president's ideas to control drug prices will do just the opposite.

Trump told pharmaceutical executives the government was paying "astronomical" prices for medicines in its health programs for older, disabled and poor people and said he would soon appoint a new U.S. Food and Drug Administration leader.

After his promise to bring down drug spending, the ARCA pharmaceutical index fell 2 percent.

Takeda CFO James Kehoe said the company was on the hunt for hit drugs.

A board committee said its five-month investigation found broad accounting problems dating back to December 2014.

The 120-patient trial showed patients taking Epidiolex achieved a median reduction in monthly convulsive seizures of 39 percent, statistically significant.

Significant obstacles discourage pharma companies from devoting the power needed to develop a patentable drug to take the plant's place.

While other drugs companies don't raise their drug prices fiftyfold, they would if it led to fat profits.

Government price fixing will produce unintended consequences in drug research and pricing.